ArticleInternational ophthalmology2025
Incidence and risk factors of ocular hypertension following ıntravitreal dexamethasone implantation: the role of baseline intraocular pressure.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the incidence of ocular hypertension (OHT) following intravitreal dexamethasone (Ozurdex) implantation and to investigate its association with baseline intraocular pressure (IOP).
methodsThis retrospective cohort study included 698 patients (1085 eyes) who received Ozurdex implantation for diabetic macular edema, macular edema secondary to retinal vein occlusion, or other retinal disorders. Only patients with a minimum follow-up duration of six months were included. IOP measurements were recorded at baseline and at week 1, and months 1, 2, 3, and 6 post-injection. These values were compared using either the paired Student's t-test or the Wilcoxon signed-rank test, depending on data distribution. Logistic regression analysis was performed to identify independent risk factors for steroid-induced ocular hypertension (SIOHT).
resultsThe incidence of SIOHT was 38% (n = 412 eyes). The mean baseline IOP was 15.73 ± 3.4 mmHg, which peaked at month 1 (17.81 ± 4.0 mmHg, p < 0.001) and month 2 (17.30 ± 4.4 mmHg, p < 0.001), then declined and returned close to baseline by month 6 (15.38 ± 4.1 mmHg, p = 0.258). Multivariate analysis revealed that age (40-50 years, OR 2.95, p = 0.001), male gender (OR 1.82, p = 0.001), and higher baseline IOP (OR 1.09, p = 0.003) were significant independent risk factors. Among SIOHT cases, 72.6% exhibited IOP elevations between 25 and 30 mmHg, 22.6% had levels exceeding 30 mmHg, and 4.8% exceeded 35 mmHg. All patients were initially treated with topical IOP-lowering medications, and only 0.7% required trabeculectomy.
conclusionIntravitreal Ozurdex implantation is associated with a significant increase in IOP, necessitating close monitoring. Higher baseline IOP and male gender were identified as major risk factors. While the majority of cases were successfully managed with topical therapy, a small proportion required surgical intervention. Further research is warranted to improve risk stratification and optimize management strategies.
Indexed as
Identifiers
40478293What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.